Select Medical (SEM) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
4 Mar, 2026Executive summary
Annual meeting scheduled for April 23, 2026, to be held virtually at 11:00 am Eastern Time.
Proxy materials are available online, and shareholders are encouraged to review them before voting.
Voting can be done online or by requesting a paper copy of the proxy materials.
Voting matters and shareholder proposals
Election of Class II Directors is on the agenda.
Advisory vote on executive compensation for named executive officers.
Ratification of PricewaterhouseCoopers LLP as independent auditor for fiscal year ending December 31, 2026.
Proposal to amend the certificate of incorporation to phase out the classified board structure.
Advisory vote on company proposal for shareholders to call a special meeting at a 25% ownership threshold.
Advisory vote on shareholder proposal for special meeting rights at a 10% ownership threshold, if presented.
Board recommends voting FOR all proposals except the 10% threshold for special meetings, which it recommends AGAINST.
Board of directors and corporate governance
Proposal to phase out the classified structure of the board, moving toward annual director elections.
Latest events from Select Medical
- Merger and compensation proposals approved; official results to be filed on Form 8-K.SEM
AGM 2026 - Special meeting to vote on $16.50/share cash merger, with board and committee unanimous support.SEM
Proxy filing - Special Committee recommends approval of a $16.50/share going-private merger, offering an 18% premium.SEM
Proxy filing - Revenue up 5%, but net income and EBITDA fell; merger expected mid-2026, guidance maintained.SEM
Q1 2026 - Independent directors back $16.50/share going-private merger, with appraisal rights and executive pay vote.SEM
Proxy filing - Board seeks annual director elections, 25% special meeting threshold, and strong governance.SEM
Proxy Filing - Q3 2025 revenue up 7.2%, EPS up 21%, margins pressured, 2025 outlook reaffirmed.SEM
Q3 2025 - Q2 revenue up 5.1% to $1.76B; Concentra IPO raised $528.8M, reducing debt by $1.9B.SEM
Q2 2024 - Revenue, net income, and liquidity improved, with Concentra IPO and debt reduction as key highlights.SEM
Q3 2024